Back to Search
SAILAJA VALLABHAJOSULA, MD
MD
Internal Medicine Physician
NPI: 1548423320IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
P1603(TX)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
OTHER
Class of 1992
Research & Publications (20)
PET imaging of leptin biodistribution and metabolism in rodents and primates.
PMID 19656493·Cell Metab·2009
7-preclinical
Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications.
PMID 19038596·Semin Nucl Med·2009
6-review
Site-specific (18)F-labeling of the protein hormone leptin using a general two-step ligation procedure.
PMID 18570424·J Am Chem Soc·2008
7-preclinical
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
PMID 18227543·Radiology·2008
7-preclinical
(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
PMID 17920348·Semin Nucl Med·2007
6-review
Investigation of the role of the base in the synthesis of [18F]FLT.
PMID 17919915·Appl Radiat Isot·2007
7-preclinical
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
PMID 17325895·Leuk Lymphoma·2007
3-trial
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
PMID 17290063·J Clin Oncol·2007
3-trial
Possible axonal regrowth in late recovery from the minimally conscious state.
PMID 16823492·J Clin Invest·2006
8-other
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
PMID 16729907·Clin Genitourin Cancer·2006
6-review
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
PMID 16362977·Cancer·2006
4-observational
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
PMID 16203821·Clin Cancer Res·2005
3-trial
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
PMID 16110029·J Clin Oncol·2005
3-trial
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
PMID 15872360·J Nucl Med·2005
3-trial
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
PMID 15837970·J Clin Oncol·2005
3-trial
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
PMID 15809486·J Nucl Med·2005
3-trial
Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?
PMID 15665617·Cancer Biother Radiopharm·2004
4-observational
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
PMID 15173215·J Clin Oncol·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 711 W BAY AREA BLVD STE 602
WEBSTER, TX 77598 - Phone
- (281) 332-2626
Quick Facts
- NPI
- 1548423320
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile